<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29030" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Simethicone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ingold</surname>
            <given-names>Curtis J.</given-names>
          </name>
          <aff>University Hospitals</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akhondi</surname>
            <given-names>Hossein</given-names>
          </name>
          <aff>University of Nevada</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Curtis Ingold declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hossein Akhondi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29030.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Simethicone is a medication used in the management and treatment of flatulence. This activity describes the indications, mechanism of action, and contraindications for simethicone as a valuable agent in the control of excess gas production. In addition, this activity will highlight the adverse event profile, dosing, and drug interactions pertinent to the interprofessional healthcare team members in the management of patients with flatulence and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of simethicone.</p></list-item><list-item><p>Describe the adverse effects of simethicone.</p></list-item><list-item><p>Review the appropriate monitoring of simethicone.</p></list-item><list-item><p>Outline some interprofessional team strategies for improving care coordination and communication. This knowledge will enhance simethicone use and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29030&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29030">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29030.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Simethicone is a silicone compound used for the management of flatulence and bloating. It relieves the discomfort produced by the presence of excess gas in the gastrointestinal tract. It was FDA approved in 1952.<xref ref-type="bibr" rid="article-29030.r1">[1]</xref>&#x000a0;Since then, it has been researched for use as a skin protectant,<xref ref-type="bibr" rid="article-29030.r2">[2]</xref>&#x000a0;for treatment&#x000a0;of Helicobacter pylori,<xref ref-type="bibr" rid="article-29030.r3">[3]</xref>,&#x000a0;and most recently in endurance athletes to reduce exercise-related GI symptoms.<xref ref-type="bibr" rid="article-29030.r4">[4]</xref>&#x000a0;Researchers also studied simethicone to treat infantile colic, but they did not find it to be effective.<xref ref-type="bibr" rid="article-29030.r5">[5]</xref>&#x000a0;Simethicone is not useful for ileus, small bowel obstruction, or constipation. Other causes of such symptoms that could be related to gallstones or heart disease should be kept in mind when utilizing simethicone. Additional signs and symptoms, such as vomiting, hematochezia, and severe abdominal tenderness, require further investigation.&#x000a0;Simethicone has also been demonstrated to be safe and well-tolerated as a component of a contrast agent to improve sonographic imaging in the abdomen.<xref ref-type="bibr" rid="article-29030.r6">[6]</xref>&#x000a0;</p>
        <p>Bernstein and Kasich performed one of the earliest studies of simethicone in 1974.&#x000a0;This study was a double-blind, randomized, placebo-controlled trial where they compared simethicone 50 mg to placebo. Placebo was identical in taste and appearance. Inclusion criteria included subjects ranging in age from 21 to 65 years, an outpatient setting, a minimum of two of the symptoms that were under evaluation. Subjects were enrolled alternately to simethicone or placebo. Forty-one patients were enrolled in the study, with twenty in the simethicone group and twenty-one in the placebo group. The assigned medication&#x000a0;was given 10 minutes before each meal and at bedtime for ten days. Changes in symptoms were evaluated around day five and again around day 10. Symptoms evaluated included gas, heartburn, fullness, full feeling, distension, stuffiness, acid indigestion, bloating, pressure, upset stomach, sour stomach, and pain after eating. Symptoms were evaluated by frequency and severity. When comparing the simethicone group to placebo, researchers observed a significant improvement in all symptoms in the simethicone group at visits on day five and day 10.<xref ref-type="bibr" rid="article-29030.r7">[7]</xref></p>
      </sec>
      <sec id="article-29030.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Simethicone is a silicone compound that functions as a non-systemic surfactant, decreasing the surface tension of gas bubbles in the GI tract. This action results in coalescence and dispersion of the gas bubbles allowing their removal from the GI tract as flatulence or belching. Simethicone causes the gas bubbles to accumulate and therefore pass more easily either through the upper GI or lower GI opening. Simethicone&#x000a0;does not appear to&#x000a0;reduce the actual production of gas in the GI tract.<xref ref-type="bibr" rid="article-29030.r8">[8]</xref>&#x000a0;</p>
        <p>Simethicone does not inhibit conditions such as lactose intolerance or medication side effects that increase the production of gas bubbles in the gastrointestinal tract.<xref ref-type="bibr" rid="article-29030.r9">[9]</xref><xref ref-type="bibr" rid="article-29030.r10">[10]</xref>&#x000a0;Intestinal gases are composed mostly of&#x000a0;nitrogen, oxygen, carbon dioxide, hydrogen, and methane.<xref ref-type="bibr" rid="article-29030.r11">[11]</xref> Simethicone is excreted in the feces.</p>
      </sec>
      <sec id="article-29030.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Simethicone administration is via the oral route. It comes manufactured as tablets, capsules, chewable films, and liquid.&#x000a0;Although it is an inert compound, simethicone should not be administered parenterally or through inhalation. It is presumed safe in infants.<xref ref-type="bibr" rid="article-29030.r12">[12]</xref> Initial studies used dosing of 50 mg ten minutes before each meal and at bedtime for ten days.<xref ref-type="bibr" rid="article-29030.r7">[7]</xref>&#x000a0;This dosing has now changed to the following recommendations:&#x000a0;</p>
        <p>Adults: 40 to 125 mg orally four times daily as needed after meals and at bedtime; the maximum daily dose is 500 mg.</p>
        <p>Children ages 2 to 12 years: 40 mg orally four times daily as needed after meals and at bedtime; the maximum daily dose is&#x000a0;480 mg.</p>
        <p>Children and infants less than two years of age: 20 mg orally four times daily as needed after meals and at bedtime; the maximum daily dose is 240 mg.</p>
        <p>Simethicone is available "over the counter" (OTC) medicine. It&#x000a0;is manufactured in combination with medications&#x000a0;such as aluminum hydroxide, magnesium hydroxide, calcium carbonate, and loperamide.</p>
      </sec>
      <sec id="article-29030.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Simethicone does not have any serious side effects. There have been reports of mild diarrhea and nausea.<xref ref-type="bibr" rid="article-29030.r6">[6]</xref>&#x000a0;Since simethicone is not absorbed orally, it is logical that systemic side effects such as kidney injury, hypertension, and hyperglycemia do not occur.<xref ref-type="bibr" rid="article-29030.r13">[13]</xref> Silicosis is a condition of pulmonary&#x000a0;fibrosis caused by&#x000a0;the inhalation of silica dust (also known as silicon dioxide). Still, there have been no reported cases of silicosis secondary to oral simethicone administration.<xref ref-type="bibr" rid="article-29030.r14">[14]</xref></p>
      </sec>
      <sec id="article-29030.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Simethicone is contraindicated in patients with a simethicone allergy.</p>
      </sec>
      <sec id="article-29030.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Simethicone is not absorbed systemically, so serum simethicone levels would not be feasible. An abdominal x-ray or computed tomography&#x000a0;can assist in monitoring outcomes. However, imaging is very rarely needed.&#x000a0;Simethicone has no significant drug interactions. There is a case report of changed absorption of levothyroxine in a child when taking simethicone. However, the overall concern is minimal.<xref ref-type="bibr" rid="article-29030.r15">[15]</xref>&#x000a0;</p>
        <p>Another case report indicated that carbamazepine toxicity could result when administering carbamazepine with&#x000a0;simethicone.<xref ref-type="bibr" rid="article-29030.r16">[16]</xref>&#x000a0;In that case, a 45-year-old man with epilepsy on carbamazepine underwent evaluation for symptoms of carbamazepine toxicity. He had an elevated serum carbamazepine level of 34.2 micrograms per milliliter (standard 4 to 11) after taking simethicone for two days. The serum carbamazepine level was obtained approximately 8 to 9 hours after his last dose of carbamazepine. His serum carbamazepine level was checked two days earlier and was 10.5&#x000a0;micrograms per milliliter. That was 10 to 11 hours after his previous carbamazepine dose. The patient denied taking any extra dosage, alcohol, herbal products, or any other new medications. In the author's conclusion, they recommended caution when prescribing simethicone in a patient taking carbamazepine.<xref ref-type="bibr" rid="article-29030.r16">[16]</xref></p>
      </sec>
      <sec id="article-29030.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Simethicone is not absorbed systemically, so it is safe in pregnancy and breastfeeding.<xref ref-type="bibr" rid="article-29030.r13">[13]</xref><xref ref-type="bibr" rid="article-29030.r17">[17]</xref>&#x000a0;There is no treatment for a simethicone overdose other than stopping the medication.&#x000a0;</p>
      </sec>
      <sec id="article-29030.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Simethicone&#x000a0;is a frequently prescribed drug by primary care providers, internists, nurse practitioners, physician assistants, and gastroenterologists to treat flatulence and bloating. A&#x000a0;knowledgeable provider can utilize simethicone to improve the patient's symptoms. In the hospital setting, simethicone can be ordered before meals and at bedtime, scheduled four times a day as needed. Hospital workflow and patient cognition is a consideration in inpatient settings. It can be more beneficial to order simethicone as a scheduled&#x000a0;regimen, so the patient receives multiple doses consistently. Simethicone is highly cost-effective in treating bloating and flatulence.&#x000a0;It is an OTC product purchased without a prescription.&#x000a0;Pharmacists can assist with proper dosing and administration.&#x000a0;Nursing can help to improve patient's utilization of simethicone. A dietician can assist a patient&#x000a0;in enhancing their&#x000a0;eating habits to avoid carbonated beverages and&#x000a0;foods that increase gastrointestinal gas formation.&#x000a0;The interprofessional team approach is the best means by which optimal patient outcomes can be achieved when using simethicone therapeutically. Thus, simethicone&#x000a0;can help to treat flatulence and bloating safely. [Level 2]</p>
      </sec>
      <sec id="article-29030.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29030&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29030">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29030/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29030">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29030.s11">
        <title>References</title>
        <ref id="article-29030.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burta</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Iacobescu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mateescu</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Nicolaie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tiuca</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pop</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical study.</article-title>
            <source>Transl Gastroenterol Hepatol</source>
            <year>2018</year>
            <volume>3</volume>
            <fpage>72</fpage>
            <pub-id pub-id-type="pmid">30511026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoggarth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waring</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greenwood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Callaghan</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A controlled, three-part trial to investigate the barrier function and skin hydration properties of six skin protectants.</article-title>
            <source>Ostomy Wound Manage</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>12</issue>
            <fpage>30</fpage>
            <page-range>30-42</page-range>
            <pub-id pub-id-type="pmid">16439809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kane</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Plaut</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Unique susceptibility of Helicobacter pylori to simethicone emulsifiers in alimentary therapeutic agents.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>500</fpage>
            <page-range>500-2</page-range>
            <pub-id pub-id-type="pmid">8834910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drobnic</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fonts</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Alday</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Petrangolini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frattini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Allegrini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Togni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vitale</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of artichoke and ginger extracts with simethicone to treat gastrointestinal symptoms in endurance athletes: a pilot study.</article-title>
            <source>Minerva Gastroenterol (Torino)</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-84</page-range>
            <pub-id pub-id-type="pmid">31994374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucassen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Assendelft</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Gubbels</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>van Eijk</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>van Geldrop</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Neven</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of treatments for infantile colic: systematic review.</article-title>
            <source>BMJ</source>
            <year>1998</year>
            <month>May</month>
            <day>23</day>
            <volume>316</volume>
            <issue>7144</issue>
            <fpage>1563</fpage>
            <page-range>1563-9</page-range>
            <pub-id pub-id-type="pmid">9596593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lev-Toaff</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Zelch</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Barone</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of a new oral contrast agent for sonography: a phase II trial.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>173</volume>
            <issue>2</issue>
            <fpage>431</fpage>
            <page-range>431-6</page-range>
            <pub-id pub-id-type="pmid">10430149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kasich</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>A double-blind trial of simethicone in functional disease of the upper gastrointestinal tract.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1974</year>
            <season>Nov-Dec</season>
            <volume>14</volume>
            <issue>11-12</issue>
            <fpage>617</fpage>
            <page-range>617-23</page-range>
            <pub-id pub-id-type="pmid">4612060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voepel-Lewis</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Malviya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>D'Agostino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hadden</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Siewert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tait</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of simethicone for the treatment of postoperative abdominal discomfort in infants.</article-title>
            <source>J Clin Anesth</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-4</page-range>
            <pub-id pub-id-type="pmid">9524891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of the effectiveness of simethicone in acute upper gastrointesinal distress.</article-title>
            <source>Curr Ther Res Clin Exp</source>
            <year>1974</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>617</fpage>
            <page-range>617-20</page-range>
            <pub-id pub-id-type="pmid">4211142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fardy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal gas.</article-title>
            <source>CMAJ</source>
            <year>1988</year>
            <month>Dec</month>
            <day>15</day>
            <volume>139</volume>
            <issue>12</issue>
            <fpage>1137</fpage>
            <page-range>1137-42</page-range>
            <pub-id pub-id-type="pmid">3058280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lasser</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Bond</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Levitt</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>The role of intestinal gas in functional abdominal pain.</article-title>
            <source>N Engl J Med</source>
            <year>1975</year>
            <month>Sep</month>
            <day>11</day>
            <volume>293</volume>
            <issue>11</issue>
            <fpage>524</fpage>
            <page-range>524-6</page-range>
            <pub-id pub-id-type="pmid">1152877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biagioli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tarasco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lingua</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moja</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Savino</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pain-relieving agents for infantile colic.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Sep</month>
            <day>16</day>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>CD009999</fpage>
            <pub-id pub-id-type="pmid">27631535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Simethicone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>3</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30000476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>SILICOSIS.</article-title>
            <source>Can Med Assoc J</source>
            <year>1934</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-9</page-range>
            <pub-id pub-id-type="pmid">20319399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skelin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lucijani&#x00107;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amid&#x0017e;i&#x00107; Klari&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Re&#x00161;i&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bakula</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liberati-&#x0010c;izmek</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gharib</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Raheli&#x00107;</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review.</article-title>
            <source>Clin Ther</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>378</fpage>
            <page-range>378-403</page-range>
            <pub-id pub-id-type="pmid">28153426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guneysel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Onur</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Denizbasi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saritemur</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Carbamazepine overdose after exposure to simethicone: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2008</year>
            <month>Jul</month>
            <day>24</day>
            <volume>2</volume>
            <fpage>242</fpage>
            <pub-id pub-id-type="pmid">18652684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29030.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagemann</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal medications and breastfeeding.</article-title>
            <source>J Hum Lact</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-62</page-range>
            <pub-id pub-id-type="pmid">10205441</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
